For founders selling into both the EU and the UK, MDR and UKCA are no longer a single regulatory track. Diverging requirements, timelines and Notified/Approved Body capacity mean the sequencing of your submissions is now a commercial decision.
The practical question is rarely “EU or UK first?” in the abstract — it depends on where your first revenue, your reference customers and your investors are. Aligning the regulatory roadmap to those milestones avoids paying twice for evidence you could have generated once.
Plan both pathways together from the start, reuse evidence where the requirements overlap, and treat capacity constraints as a scheduling input rather than a surprise.
